P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator's choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy. (April 2023)

Record Type:
Journal Article
Title:
P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator's choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy. (April 2023)
Main Title:
P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator's choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy
Authors:
Bardia, A.
Pusztai, L.
Albain, K.
Kalinsky, K.
Hershman, D.
Barlow, W.
Tokunaga, E.
Ciruelos, E.M.
Loirat, D.
Isaacs, C.
Testa, L.
Dry, H.
Kozarski, R.
Maxwell, M.
Harbeck, N.
Sharma, P.
Abstract:
Is Part Of:
Breast. Volume 68(2023)
Journal:
Breast
Issue:
Volume 68(2023)
Issue Display:
Volume 68, Issue 2023 (2023)
Year:
2023
Volume:
68
Issue:
2023
Issue Sort Value:
2023-0068-2023-0000
Page Start:
S23
Page End:
Publication Date:
2023-04
Subjects:
Breast -- Diseases -- Periodicals
Breast -- Tumors -- Periodicals
Breast -- Periodicals
Electronic journals
Periodicals
616
Journal URLs:
http://www.sciencedirect.com/science/journal/09609776 ↗
http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=0960-9776;screen=info;ECOIP ↗
http://www.harcourt-international.com/journals/brst/ ↗
http://www.clinicalkey.com/dura/browse/journalIssue/09609776 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/09609776 ↗
http://www.elsevier.com/journals ↗
DOI:
10.1016/S0960-9776(23)00137-6 ↗
Languages:
English
ISSNs:
0960-9776
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - 2277.492700
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:
26390.xml